Cargando…
Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
The majority of human breast cancer is estrogen receptor alpha (ER) positive. While anti-estrogens/aromatase inhibitors are initially effective, resistance to these drugs commonly develops. Therapy-resistant tumors often retain ER signaling, via interaction with critical oncogenic coregulator protei...
Autores principales: | Raj, Ganesh V, Sareddy, Gangadhara Reddy, Ma, Shihong, Lee, Tae-Kyung, Viswanadhapalli, Suryavathi, Li, Rui, Liu, Xihui, Murakami, Shino, Chen, Chien-Cheng, Lee, Wan-Ru, Mann, Monica, Krishnan, Samaya Rajeshwari, Manandhar, Bikash, Gonugunta, Vijay K, Strand, Douglas, Tekmal, Rajeshwar Rao, Ahn, Jung-Mo, Vadlamudi, Ratna K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548489/ https://www.ncbi.nlm.nih.gov/pubmed/28786813 http://dx.doi.org/10.7554/eLife.26857 |
Ejemplares similares
-
Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers
por: Viswanadhapalli, Suryavathi, et al.
Publicado: (2019) -
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways
por: Zhou, Mei, et al.
Publicado: (2019) -
Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer
por: Liu, Jinyou, et al.
Publicado: (2017) -
Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma
por: Sareddy, Gangadhara R., et al.
Publicado: (2016) -
Histone deacetylase inhibitors enhance estrogen receptor beta expression and augment agonist-mediated tumor suppression in glioblastoma
por: Pratap, Uday P, et al.
Publicado: (2021)